AT2/Angiotensin Receptor 2/AGTR2 Double Nickase Plasmid (h): sc-418156-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- AT2/Angiotensin Receptor 2/AGTR2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- AT2/Angiotensin Receptor 2/AGTR2 Double Nickase Plasmid (h) and AT2/Angiotensin Receptor 2/AGTR2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting AGTR2. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AT2/Angiotensin Receptor 2/AGTR2 Double Nickase Plasmid (h) | sc-418156-NIC | 20 µg | $410.00 | |||
AT2/Angiotensin Receptor 2/AGTR2 Double Nickase Plasmid (h2) | sc-418156-NIC-2 | 20 µg | $410.00 |
AGTR2 encodes angiotensin II receptor type 2 (AT2), a seven-transmembrane GPCR that binds angiotensin II within the renin–angiotensin system and modulates signaling distinct from AGTR1. AT2 couples to pathways that influence nitric oxide/cGMP production, phosphatase activity, and MAPK dynamics, shaping cellular programs such as differentiation, neurite outgrowth, apoptosis, and inflammatory tone in a context-dependent manner. AGTR2 expression is prominent during development and is regulated in adult vascular, cardiac, renal, and neural tissues, where it can affect vascular remodeling and tissue injury responses. Altered AGTR2 signaling or expression has been associated with cardiovascular and renal pathophysiology and has been investigated in settings including hypertension, fibrosis, and neuroinflammation.
AT2/Angiotensin Receptor 2/AGTR2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the AGTR2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within AGTR2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt AGTR2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of AGTR2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.